Clinical trialPhase 1 / Phase 2Active not recruiting
Pancrelipase in People With Pancreatic Ductal Adenocarcinoma (PDAC)
A Randomized Double Blind Study of Pancreatic Enzyme Replacement Therapy for Patients With Metastatic Pancreatic Ductal Adenocarcinoma
- Outcome
- Ongoing
- Phase
- Phase 1 / Phase 2
- Status
- Active not recruiting
- Study type
- Interventional
- Start
- 30 November 2022
- Expected end
- 30 November 2026
- Enrollment
- 17 participants
- Sites
- 7
- Primary outcomes
- Change in body mass index/BMI from baseline to 4 months
- Sponsor
- Other
- Results posted
- No
- Last update
- 25 February 2026
These are registry fields. A trial card, with population, design, endpoints and result direction each tied to a quote, is not in the data yet.
Ask this document
Answers come only from this document’s own text, as highlighted quotes. If it doesn’t say, you are told so instead of given a guess.
Try
Source text
Brief summary public domain (ClinicalTrials.gov)
The main purpose of this study is to see how pancrelipase affects the body mass index (BMI) in people with metastatic PDAC. BMI is a measure based on a person's height and weight. Other study goals are to explore two different dosing schedules of pancrelipase and to evaluate pancrelipase in people who do not have symptoms of EPI.